Literature DB >> 27858572

Correlation between GH and IGF-1 during treatment for acromegaly.

Edward H Oldfield1, John A Jane1, Michael O Thorner2, Carrie L Pledger1, Jason P Sheehan1, Mary Lee Vance2.   

Abstract

OBJECTIVE The relationship between growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients with acromegaly as serial levels drop over time after treatment has not been examined previously. Knowledge of this relationship is important to correlate pretreatment levels that best predict response to treatment. To examine the correlation between GH and IGF-1 and IGF-1 z-scores over a wide range of GH levels, the authors examined serial GH and IGF-1 levels at intervals before and after surgery and radiosurgery for acromegaly. METHODS This retrospective analysis correlates 414 pairs of GH and IGF-1 values in 93 patients with acromegaly. RESULTS Absolute IGF-1 levels increase linearly with GH levels only up to a GH of 4 ng/ml, and with IGF-1 z-scores only to a GH level of 1 ng/ml. Between GH levels of 1 and 10 ng/ml, increases in IGF-1 z-scores relative to changes in GH diminish and then plateau at GH concentrations of about 10 ng/ml. From patient to patient there is a wide range of threshold GH levels beyond which IGF-1 increases are no longer linear, GH levels at which the IGF-1 response plateaus, IGF-1 levels at similar GH values after the IGF-1 response plateaus, and of IGF-1 levels at similar GH levels. CONCLUSIONS In acromegaly, although IGF-1 levels represent a combination of the integrated effects of GH secretion and GH action, the tumor produces GH, not IGF-1. Nonlinearity between GH and IGF-1 occurs at GH levels far below those previously recognized. To monitor tumor activity and tumor viability requires measurement of GH levels.

Entities:  

Keywords:  CV = coefficient of variation; GH = growth hormone; IGF-1; IGF-1 = insulin-like growth factor–1; acromegaly; growth hormone; pituitary surgery; radiosurgery

Mesh:

Substances:

Year:  2016        PMID: 27858572     DOI: 10.3171/2016.8.JNS161123

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  Predictors of surgical outcome and early criteria of remission in acromegaly-some controversial issues.

Authors:  Zihao Wang; Bing Xing
Journal:  Endocrine       Date:  2018-06-25       Impact factor: 3.633

Review 2.  Association between insulin-like growth factor-1 and cardiovascular events: a systematic review and dose-response meta-analysis of cohort studies.

Authors:  T Li; Y Zhao; X Yang; Y Feng; Y Li; Y Wu; M Zhang; X Li; H Hu; J Zhang; L Yuan; Y Liu; X Sun; P Qin; C Chen; D Hu
Journal:  J Endocrinol Invest       Date:  2022-05-21       Impact factor: 4.256

3.  Bone and body composition analyses by DXA in adults with GH deficiency: effects of long-term replacement therapy.

Authors:  Alessandro Rossini; Roberto Lanzi; Carlotta Galeone; Claudio Pelucchi; Mario Pennacchioni; Francesca Perticone; Marcella Sirtori; Marco Losa; Alessandro Rubinacci
Journal:  Endocrine       Date:  2021-07-30       Impact factor: 3.633

4.  Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study.

Authors:  Eva C Coopmans; Mark R Postma; Thalijn L C Wolters; Sebastiaan W F van Meyel; Romana Netea-Maier; André P van Beek; Sebastian J C M M Neggers
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 5.  A Consensus Statement on acromegaly therapeutic outcomes.

Authors:  Shlomo Melmed; Marcello D Bronstein; Philippe Chanson; Anne Klibanski; Felipe F Casanueva; John A H Wass; Christian J Strasburger; Anton Luger; David R Clemmons; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2018-09       Impact factor: 43.330

6.  Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.

Authors:  Ajay Madan; Stacy Markison; Stephen F Betz; Alan Krasner; Rosa Luo; Theresa Jochelson; Jason Lickliter; R Scott Struthers
Journal:  Pituitary       Date:  2022-01-09       Impact factor: 4.107

7.  Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.

Authors:  Júnia R O L Schweizer; Katharina Schilbach; Michael Haenelt; Alexandre V Giannetti; Mariana F Bizzi; Beatriz S Soares; Eduardo Paulino; Jochen Schopohl; Sylvère Störmann; Antônio Ribeiro-Oliveira; Martin Bidlingmaier
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

8.  A Zebrafish Acromegaly Model Elevates DNA Damage and Impairs DNA Repair Pathways.

Authors:  Abdalla Elbialy; Shuichi Asakawa; Shugo Watabe; Shigeharu Kinoshita
Journal:  Biology (Basel)       Date:  2018-10-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.